Guidance on the use of paclitaxel in the treatment of ovarian cancer

View the summary and implementation tools

This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta55

Important information about this guidance

This guidance replaces 'Ovarian cancer – taxanes' (NICE Technology Appraisal Guidance No 3) issued in May 2000.

This guidance has been partially updated by 'Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review)' (NICE technology appraisal guidance 91 [TA91]. The recommendations that have been updated are indicated in section 1 below.

This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp